J. Collet

Helmut Baumgartner, Volkmar Falk, Marco Valgimigli, 2014, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

Pre-hospital detection of acute myocardial infarction with ultra-rapid human fatty acid-binding protein (H-FABP) immunoassay.

P. Coriat, G. Montalescot, J. Collet, 2007, International journal of cardiology.

[2011 ESC guidelines on the diagnosis and treatment of peripheral artery diseases].

Raimund Erbel, Marco Roffi, Don Poldermans, 2012, Revue medicale de Liege.

2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Ca

Volkmar Falk, Marco Valgimigli, Fernando Alfonso, 2014, European heart journal.

Point-of-care genetic profiling and/or platelet function testing in acute coronary syndrome

E. Vicaut, G. Montalescot, J. Hulot, 2015, Thrombosis and Haemostasis.

ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

Baris Gencer, Marco Valgimigli, Marco Roffi, 2011 .

Genetic and platelet function testing of antiplatelet therapy for percutaneous coronary intervention: the ARCTIC-GENE study

E. Vicaut, E. Belle, G. Montalescot, 2015, European Journal of Clinical Pharmacology.

High On-Treatment Platelet Reactivity as a Risk Factor for Secondary Prevention After Coronary Stent Revascularization: A Landmark Analysis of the ARCTIC Study

E. Vicaut, G. Montalescot, M. Kerneis, 2014, Circulation.

Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention

K. Huber, J. Collet, D. Sibbing, 2013, European heart journal.

Personalized antiplatelet therapy: the wrong approach?

G. Montalescot, J. Collet, 2013, Archives of cardiovascular diseases.

Bedside monitoring to adjust antiplatelet therapy for coronary stenting.

E. Vicaut, G. Montalescot, M. Kerneis, 2012, The New England journal of medicine.

Open issues in transcatheter aortic valve implantation. Part 2: procedural issues and outcomes after transcatheter aortic valve implantation.

Jeroen J. Bax, J. Leipsic, P. Serruys, 2014, European heart journal.

2018 ESC/EACTS Guidelines on myocardial revascularization.

Volkmar Falk, Fernando Alfonso, Peter Jüni, 2018, European heart journal.

Non-cardiac surgery in patients with coronary stents: the RECO study

C. Samama, S. Jaber, J. Collet, 2011, Heart.

Real-life management of dual antiplatelet therapy interruption: the REGINA survey.

E. Vicaut, P. Coriat, G. Montalescot, 2009, Archives of cardiovascular diseases.

Impact of Prior Use or Recent Withdrawal of Oral Antiplatelet Agents on Acute Coronary Syndromes

J. Golmard, G. Montalescot, J. Collet, 2004, Circulation.

Networks for improving care in patients with acute coronary syndrome: A framework

P. Kolh, D. Ardissino, M. Postma, 2014, Acute cardiac care.

Adverse events while awaiting myocardial revascularization: a systematic review and meta-analysis

P. Kolh, P. Schauerte, G. Filippatos, 2017, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

2014 ESC/EACTS guidelines on myocardial revascularization.

P. Kolh, P. Schauerte, G. Filippatos, 2015, Revista espanola de cardiologia.

Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial

E. Vicaut, E. Belle, G. Montalescot, 2016, The Lancet.

Indirect Comparison of the Efficacy and Safety of Alirocumab and Evolocumab: A Systematic Review and Network Meta-Analysis.

E. Ollier, C. Indolfi, R. Mehran, 2020, European heart journal. Cardiovascular pharmacotherapy.

Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharmacotherapy.

B. Lewis, V. Aboyans, L. Mazzolai, 2021, European heart journal.

Management of antiplatelet therapy for non-elective invasive procedures or bleeding complications: Proposals from the French Working Group on Perioperative Haemostasis (GIHP) and the French Study Group on Thrombosis and Haemostasis (GFHT), in collaboration with the French Society for Anaesthesia and

M. Mazighi, J. Collet, P. Fontana, 2019, Archives of cardiovascular diseases.

Management of antiplatelet therapy in patients undergoing elective invasive procedures. Proposals from the French Working Group on perioperative haemostasis (GIHP) and the French Study Group on thrombosis and haemostasis (GFHT). In collaboration with the French Society for Anaesthesia and Intensive

S. Susen, J. Collet, P. Fontana, 2018, Anaesthesia, critical care & pain medicine.

Evolving strategies in the management of acute coronary syndromes with oral antiplatelet agents

J. Jukema, B. Meier, J. Collet, 2012 .

Interval From Initiation of Prasugrel to Coronary Angiography in Patients With Non-ST-Segment Elevation Myocardial Infarction.

E. Vicaut, D. Dudek, G. Montalescot, 2019, Journal of the American College of Cardiology.

Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy.

J. Soria, C. Soria, J. Weisel, 2000, Arteriosclerosis, thrombosis, and vascular biology.

Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis.

G. Montalescot, J. Collet, L. Payot, 2004, JAMA.

The acute reperfusion management of STEMI in patients with impaired glucose tolerance and type 2 diabetes

G. Montalescot, J. Collet, 2005, Diabetes & vascular disease research.

Antithrombotic Therapy Following Transcatheter Aortic Valve Replacement

J. Collet, P. Guedeney, C. Granger, 2022, Journal of clinical medicine.

Transcatheter aortic valve thrombosis: Data from a French multicenter cohort analysis

J. Collet, T. Lhermusier, N. Combaret, 2021, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Antithrombotic Therapy After Transcatheter Aortic Valve Replacement.

G. Dangas, S. Windecker, G. Montalescot, 2021, JACC. Cardiovascular interventions.

Effect of oral anticoagulation on clinical outcomes and haemodynamic variables after successful transcatheter aortic valve implantation.

E. Vicaut, P. Leprince, G. Montalescot, 2020, Archives of cardiovascular diseases.

Antithrombotic therapy in patients undergoing transcatheter aortic valve implantation

E. Grove, J. Collet, J. T. ten Berg, 2019, Heart.

Oral anti‐Xa anticoagulation after trans‐aortic valve implantation for aortic stenosis: The randomized ATLANTIS trial

E. Vicaut, P. Leprince, F. Neumann, 2018, American heart journal.

Coronary artery disease Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction : a collaborative meta-analysis of randomized trials

Marc P. Bonaca, Deepak L. Bhatt, M. Sabatine, 2016 .

Impact of prolonged dual antiplatelet therapy after acute myocardial infarction on 5-year mortality in the FAST-MI 2005 registry.

J. Ferrières, J. Collet, N. Danchin, 2015, International journal of cardiology.

Antithrombotic and antiplatelet therapy in TAVI patients: a fallow field?

G. Montalescot, J. Collet, 2013, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Premature withdrawal and alternative therapies to dual oral antiplatelet therapy

G. Montalescot, J. Collet, 2006 .

Amino-Fucoidan as a Vector for rtPA-Induced Fibrinolysis in Experimental Thrombotic Events

J. Michel, J. Collet, F. Chaubet, 2018, Thrombosis and Haemostasis.

Triple antithrombotic therapy in atrial fibrillation patients with acute coronary syndromes or undergoing percutaneous coronary intervention or transcatheter aortic valve replacement.

P. Kirchhof, G. Lip, G. Boriani, 2015, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association

P. Kirchhof, G. Lip, G. Boriani, 2014, European heart journal.

Impact of fondaparinux versus enoxaparin on in-hospital bleeding and 1-year death in non-ST-segment elevation myocardial infarction. FAST-MI (French Registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction) 2010

J. Collet, N. Danchin, T. Simon, 2015, European heart journal. Acute cardiovascular care.

Long-term secondary prevention after high-risk stenting: a good drug for a bad stent.

G. Montalescot, J. Collet, J. Silvain, 2015, Circulation.

Comparison of bleeding complications and one-year survival of low molecular weight heparin versus unfractioned heparin for acute myocardial infarction in elderly patients. The FAST-MI registry.

J. Ferrières, J. Collet, N. Danchin, 2013, International journal of cardiology.

Current antiplatelet options for NSTE-ACS patients.

G. Montalescot, J. Collet, J. Silvain, 2012, QJM : monthly journal of the Association of Physicians.

Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.

G. Montalescot, J. Collet, J. Silvain, 2012, JAMA.

Acute coronary syndromes: considerations for improved acceptance and implementation of management guidelines

P. Kolh, F. Van de Werf, S. Silber, 2012, Expert review of cardiovascular therapy.

Clinical effects and outcomes with new P2Y12 inhibitors in ACS

J. Collet, S. O’Connor, 2012, Fundamental & clinical pharmacology.

Endoscopy and antiplatelet agents. European Society of Gastrointestinal Endoscopy (ESGE) Guideline.

C. Boustière, T. Baron, J. Collet, 2011, Endoscopy.

Immediate vs delayed intervention for acute coronary syndromes: a randomized clinical trial.

E. Vicaut, J. Dubois-Randé, G. Montalescot, 2009, JAMA.

Thrombotic and bleeding events after coronary stenting according to clopidogrel and aspirin platelet reactivity: VerifyNow French Registry (VERIFRENCHY).

G. Montalescot, J. Collet, F. Beygui, 2014, Archives of cardiovascular diseases.

Switching acute coronary syndrome patients from prasugrel to clopidogrel.

G. Montalescot, M. Kerneis, J. Collet, 2013, JACC. Cardiovascular interventions.

An evidence-based review of current anti-platelet options for STEMI patients.

G. Montalescot, J. Collet, J. Silvain, 2013, International journal of cardiology.

Antithrombotic Therapy in Acute Coronary Syndromes: Current Evidence and Ongoing Issues Regarding Early and Late Management

J. Collet, P. Guedeney, 2021, Thrombosis and Haemostasis.

Early Aspirin Discontinuation Following Acute Coronary Syndrome or Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

C. Indolfi, G. Montalescot, M. Kerneis, 2020, Journal of clinical medicine.

Diagnosis and Management of Acute Coronary Syndrome: What is New and Why? Insight From the 2020 European Society of Cardiology Guidelines

J. Collet, P. Guedeney, 2020, Journal of clinical medicine.

2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European

G. Lip, L. Fauchier, M. Valgimigli, 2018, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS trials.

G. Hindricks, H. Heidbuchel, T. Potpara, 2019, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

Rationale and design of POPular-TAVI: antiPlatelet therapy fOr Patients undergoing Transcatheter Aortic Valve Implantation.

P. Stella, P. van der Harst, K. Huber, 2016, American heart journal.

Management of antithrombotic therapy in atrial fibrillation patientspresentingwith acutecoronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart

L. Fauchier, T. Potpara, J. Tamargo, 2014 .

Periprocedural myocardial infarction and injury in elective coronary stenting

G. Helft, G. Montalescot, M. Kerneis, 2018, European heart journal.

Thrombus composition in sudden cardiac death from acute myocardial infarction.

X. Jouven, J. Weisel, G. Montalescot, 2017, Resuscitation.

Intravenous enoxaparin anticoagulation in percutaneous left atrial cardiac procedures.

G. Montalescot, M. Kerneis, J. Collet, 2017, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Switching between thienopyridines in patients with acute myocardial infarction and quality of care

J. Ferrières, J. Collet, N. Danchin, 2016, Open Heart.

Intravenous Clopidogrel (MDCO-157) Compared with Oral Clopidogrel: The Randomized Cross-Over AMPHORE Study

G. Montalescot, J. Hulot, J. Collet, 2016, American Journal of Cardiovascular Drugs.

Efficacy of Ex Vivo Autologous and In Vivo Platelet Transfusion in the Reversal of P2Y12 Inhibition by Clopidogrel, Prasugrel, and Ticagrelor: The APTITUDE Study

P. Leprince, G. Montalescot, J. Amour, 2015, Circulation. Cardiovascular interventions.

Dual antiplatelet treatment after stenting – Authors' reply

E. Vicaut, G. Montalescot, J. Collet, 2015, The Lancet.

Pretreatment with P2Y12 Inhibitors in Non–ST-Segment–Elevation Acute Coronary Syndrome: An Outdated and Harmful Strategy

G. Montalescot, J. Collet, J. Silvain, 2014, Circulation.

Myocardial infarction after aspirin cessation in stable coronary artery disease patients.

P. Steg, J. Collet, D. Himbert, 2000, International journal of cardiology.

Percutaneous coronary intervention after fibrinolysis: a multiple meta-analyses approach according to the type of strategy.

G. Montalescot, J. Collet, M. Le May, 2006, Journal of the American College of Cardiology.

Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials.

S. Steinhubl, H. White, C. Bode, 2007, Archives of internal medicine.

Abstract 2126: CYP2C19 Genetic Variants and Clinical Outcomes With Clopidogrel: A Collaborative Meta-Analysis

J. Mega, B. Horne, Jeffrey L. Anderson, 2009 .

New P2Y12 inhibitors versus clopidogrel in percutaneous coronary intervention: a meta-analysis.

G. Montalescot, J. Collet, D. Brieger, 2010, Journal of the American College of Cardiology.

Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis

E. Vicaut, K. Huber, G. Montalescot, 2012, BMJ : British Medical Journal.

A direct comparison of intravenous enoxaparin with unfractionated heparin in primary percutaneous coronary intervention (from the ATOLL trial).

E. Vicaut, K. Huber, G. Montalescot, 2013, The American journal of cardiology.

Syndromes : A Randomized Clinical Trial Immediate vs Delayed Intervention for Acute Coronary

J. Collet, J. Silvain, F. Beygui, 2009 .

Respective role of surface electrocardiogram and His bundle recordings to assess the risk of atrioventricular block after transcatheter aortic valve replacement.

J. Collet, R. Frank, F. Hidden‐Lucet, 2017, International journal of cardiology.

Do Patients need Lifelong β-Blockers after an Uncomplicated Myocardial Infarction?

G. Montalescot, M. Kerneis, J. Collet, 2019, American Journal of Cardiovascular Drugs.

Optimal timing of initiation of oral P2Y12-receptor antagonist therapy in patients with non-ST elevation acute coronary syndromes. Lessons learnt from the ACCOAST-trial

D. Ardissino, J. López-Sendón, G. Montalescot, 2016, European heart journal. Acute cardiovascular care.

Reply: Not All NSTEMIs Are Created Equal.

E. Vicaut, D. Dudek, G. Montalescot, 2015, Journal of the American College of Cardiology.

Platelet Protease Nexin-1, a Serpin That Strongly Influences Fibrinolysis and Thrombolysis

J. Collet, B. Ho-Tin-Noé, B. Richard, 2010, Circulation.

Long-Term Evolution of Premature Coronary Artery Disease.

E. Vicaut, G. Montalescot, J. Hulot, 2019, Journal of the American College of Cardiology.

Optimal Duration of Dual Antiplatelet Therapy After DES Implantation

H. Suryapranata, G. De Luca, A. Colombo, 2016, Angiology.

Antiplatelet options for secondary prevention in acute coronary syndromes

G. Montalescot, J. Collet, J. Silvain, 2011, Expert review of cardiovascular therapy.

Indirect Transfer to Catheterization Laboratory for ST Elevation Myocardial Infarction Is Associated With Mortality Independent of System Delays: Insights From the France-PCI Registry

G. Montalescot, J. Collet, F. Beygui, 2022, Frontiers in Cardiovascular Medicine.

Prognosis of moderate coronary artery lesions in heart transplant patients.

M. Dalby, J. Collet, R. Choussat, 2003, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

FXIII-A Leu34 genetic variant in premature coronary artery disease: A genotype – phenotype case control study

J. Weisel, G. Montalescot, J. Hulot, 2011, Thrombosis and Haemostasis.

Platelet reactivity in human immunodeficiency virus infected patients on dual antiplatelet therapy for an acute coronary syndrome: the EVERE2ST-HIV study

G. Montalescot, J. Hulot, M. Kerneis, 2017, European heart journal.

Prasugrel compared with high-dose clopidogrel in acute coronary syndrome

G. Montalescot, Junxiang Luo, J. Collet, 2009, Thrombosis and Haemostasis.

[2018 ESC/EACTS Guidelines on myocardial revascularization. The Task Force on myocardial revascularization of the European Society of Cardiology (ESC) and European Association for Cardio-Thoracic Surgery (EACTS)].

P. Seferovic, P. Jüni, V. Falk, 2019, Giornale italiano di cardiologia.

Questions and Answers on Diagnosis and Management of Patients with Peripheral Arterial Diseases: A Companion Document of the 2017 ESC Guidelines for the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS).

G. Hindricks, P. Kolh, P. Ponikowski, 2017, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

Systematic detection of polyvascular disease combined with aggressive secondary prevention in patients presenting with severe coronary artery disease: The randomized AMERICA Study.

E. Vicaut, G. Montalescot, J. Collet, 2018, International journal of cardiology.

Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: ATLANTIC-Morphine

W. Cantor, B. Merkely, K. Huber, 2018, American Journal of Cardiovascular Drugs.

Platelet function testing in acute cardiac care – is there a role for prediction or prevention of stent thrombosis and bleeding?

A. Jaffe, B. Merkely, K. Huber, 2014, Thrombosis and Haemostasis.

Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study

G. Montalescot, J. Hulot, M. Kerneis, 2014, European Journal of Clinical Pharmacology.

Impact of polyvascular disease on baseline characteristics, management and mortality in acute myocardial infarction. The Alliance project.

J. Collet, N. Danchin, P. Steg, 2010, Archives of cardiovascular diseases.

Outcomes Following Patent Foramen Ovale Percutaneous Closure According to the Delay From Last Ischemic Event.

G. Montalescot, J. Collet, P. Guedeney, 2022, The Canadian journal of cardiology.

Risk-Benefit Profile of Longer-Than-1-Year Dual-Antiplatelet Therapy Duration After Drug-Eluting Stent Implantation in Relation to Clinical Presentation: A Pairwise Meta-Analysis of 6 Trials and 21 457 Patients

E. Vicaut, G. Stone, M. Valgimigli, 2019, Circulation. Cardiovascular interventions.

Reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and meta-analysis

G. Montalescot, M. Kerneis, J. Collet, 2014, BMJ.

Bleeding complications in primary percutaneous coronary intervention of ST‐elevation myocardial infarction in a radial center

G. Montalescot, D. Costagliola, J. Collet, 2012, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Optimal Use of Thienopyridines in Non-ST-Elevation Acute Coronary Syndrome Following CURRENT-OASIS 7

G. Montalescot, J. Collet, J. Silvain, 2011, Circulation. Cardiovascular interventions.

Non-ST-segment elevation acute coronary syndromes: an algorithm for decision.

M. Bertrand, G. Montalescot, J. Collet, 2007, European Heart Journal.

Impact of anticoagulation on ionic and nonionic contrast media effect on thrombogenesis and fibrinolysis: The PEPCIT study

G. Montalescot, J. Collet, J. Silvain, 2012, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Cardiac events after low osmolar ionic or isosmolar nonionic contrast media utilization in the current era of coronary angioplasty

G. Helft, G. Montalescot, J. Collet, 2006, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Antithrombotic Therapy for Patients With Left Ventricular Mural Thrombus.

E. Vicaut, G. Montalescot, M. Kerneis, 2020, Journal of the American College of Cardiology.

Efficacy and Safety of Glycoprotein IIb/IIIa Inhibitors on Top of Ticagrelor in STEMI: A Subanalysis of the ATLANTIC Trial

E. Vicaut, W. Cantor, B. Merkely, 2019, Thrombosis and Haemostasis.

Safety and efficacy of IIb/IIIa inhibitors in combination with highly active oral antiplatelet regimens in acute coronary syndromes: A meta-analysis of pivotal trials

G. Montalescot, J. Collet, F. Beygui, 2017, Platelets.

Anticoagulation in Acute Coronary Syndrome-State of the Art.

G. Montalescot, T. Nafee, M. Kerneis, 2018, Progress in cardiovascular diseases.

Impact of preoperative maintenance or interruption of aspirin on thrombotic and bleeding events after elective non-cardiac surgery: the multicentre, randomized, blinded, placebo-controlled, STRATAGEM trial.

F. Tubach, P. Ravaud, C. Samama, 2011, British journal of anaesthesia.

Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis.

S. Urien, G. Montalescot, J. Hulot, 2005, British journal of clinical pharmacology.

Prehospital ticagrelor in ST-segment elevation myocardial infarction.

E. Vicaut, W. Cantor, B. Merkely, 2014, The New England journal of medicine.

P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention

Deepak L. Bhatt, Sunil V. Rao, P. Serruys, 2022, Nature Reviews Cardiology.

Aspirin-Free Strategies After PCI: Still Not Out of the Twilight.

G. Montalescot, J. Collet, M. Zeitouni, 2019, Journal of the American College of Cardiology.

Double vs. triple antithrombotic therapy in atrial fibrillation patients undergoing percutaneous coronary intervention: does clinical presentation matter?

J. Collet, A. Rubboli, 2020, European heart journal. Cardiovascular pharmacotherapy.

Acute Cardiovascular Care : The STREAM Trial *

J. Collet, F. Werf, 2018 .

Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis.

G. Montalescot, J. Collet, L. Payot, 2004, JAMA.

Individualised Antiplatelet Therapy - Is There a Role for Platelet Function Testing in Routine Clinical Practice?

J. Collet, J. W. Werkum, 2009 .

Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study.

G. Montalescot, J. Collet, L. Jacquemin, 2008, JACC. Cardiovascular interventions.

lopidogrel 150 mg / day to Overcome Low esponsiveness in Patients Undergoing Elective ercutaneous Coronary Intervention esults From the VASP-02 ( Vasodilator-Stimulated Phosphoprotein-02 ) andomized Study

G. Montalescot, J. Collet, L. Jacquemin, 2008 .

Screening of unrecognized peripheral arterial disease (PAD) using ankle-brachial index in high cardiovascular risk patients free from symptomatic PAD.

J. Collet, P. Cacoub, D. Huet, 2009, Journal of vascular surgery.

Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up.

E. Vicaut, A. Kastrati, G. Montalescot, 2007, European heart journal.

Optimal time for catheterization in NSTE-ACS patients with impaired renal function: insights from the ABOARD Study.

E. Vicaut, G. Montalescot, J. Collet, 2013, International journal of cardiology.

Heparin or enoxaparin anticoagulation for primary percutaneous coronary intervention

G. Montalescot, D. Costagliola, J. Collet, 2011, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Impact of age on management and outcome of acute coronary syndrome: observations from the Global Registry of Acute Coronary Events (GRACE).

Á. Avezum, K. Eagle, J. Gore, 2005, American heart journal.

Preserving cardiac function in the hypertensive patient: why renal parameters hold the key.

G. Montalescot, J. Collet, 2005, European heart journal.

Prognostic significance of renal insufficiency in patients presenting with acute coronary syndrome (the Prospective Multicenter SYCOMORE study).

J. Dubois-Randé, G. Montalescot, P. Steg, 2004, The American journal of cardiology.

Rare genotypes of protein Z gene are a risk factor for premature myocardial infarction but not protein Z plasma level

C. Soria, G. Montalescot, J. Collet, 2009, Thrombosis and Haemostasis.

Cerebral Embolism: A Silent Iatrogenic Complication of TAVR That Needs Voiced Consideration.

G. Montalescot, J. Collet, O. Barthelemy, 2016, Journal of the American College of Cardiology.

CYP2C19 But Not PON1 Genetic Variants Influence Clopidogrel Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy in Post–Myocardial Infarction Patients

S. Scott, G. Montalescot, J. Hulot, 2011, Circulation. Cardiovascular interventions.

CYP 2 C 19 But Not PON 1 Genetic Variants Influence Clopidogrel Pharmacokinetics , Pharmacodynamics , and Clinical Efficacy in Post – Myocardial Infarction Patients

S. Scott, G. Montalescot, J. Hulot, 2011 .

Debate: Prasugrel rather than ticagrelor is the preferred treatment for NSTE-ACS patients who proceed to PCI and pretreatment should not be performed in patients planned for an early invasive strategy Introduction

Deepak L. Bhatt, F. Rutten, B. Lewis, 2021 .

Optimal timing of invasive angiography in non-ST-segment elevation acute coronary syndromes-do we need more data?

H. Thiele, J. Collet, A. Jobs, 2020, European heart journal.

Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials.

M. Dalby, J. Golmard, G. Montalescot, 2003, Journal of the American College of Cardiology.

Le traitement antithrombotique à la phase aiguë de l'angor instable

J. Collet, 2001 .

A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention.

E. Vicaut, G. Montalescot, J. Collet, 2002, Journal of the American College of Cardiology.

Glycoprotein IIb/IIIa Inhibition—Reply

G. Montalescot, J. Collet, L. Payot, 2004 .

Coronary revascularization in the diabetic patient.

G. Montalescot, M. Kerneis, J. Collet, 2014, Circulation.

[Platelet aggregation and antiplatelet agents in acute coronary syndromes].

G. Montalescot, J. Collet, R. Choussat, 2004, Medecine sciences : M/S.

Presentation and prognosis of cardiac involvement in hepatitis C virus-related vasculitis.

P. Cluzel, J. Collet, D. Sène, 2013, The American journal of cardiology.

Measures of Platelet Activation and Aggregation

G. Montalescot, J. Collet, 2006 .

Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel, and eptifibatide (PEACE) study.

E. Vicaut, M. Dalby, G. Montalescot, 2004, Journal of the American College of Cardiology.

Effect of intracoronary administration of AAV1/SERCA2a on ventricular remodelling in patients with advanced systolic heart failure: results from the AGENT‐HF randomized phase 2 trial

E. Vicaut, P. Leprince, P. Cluzel, 2017, European journal of heart failure.

Management of direct oral anticoagulants in patients undergoing elective surgeries and invasive procedures: Updated guidelines from the French Working Group on Perioperative Hemostasis (GIHP) - September 2015.

C. Samama, S. Susen, J. Collet, 2017, Anaesthesia, critical care & pain medicine.

Pretreatment with P2Y12 inhibitors in non-ST-segment elevation acute coronary syndrome: Time to revise the guidelines?

G. Montalescot, J. Collet, J. Silvain, 2014, Archives of cardiovascular diseases.

Dosing Strategy in Patients with Renal Failure Receiving Enoxaparin for the Treatment of non‐ST‐segment Elevation Acute Coronary Syndrome

S. Urien, G. Montalescot, J. Hulot, 2005, Clinical pharmacology and therapeutics.

E. Vicaut, M. Dalby, G. Montalescot, 2004, Journal of the American College of Cardiology.

Resumption of Antiplatelet Therapy after Major Bleeding

K. Huber, J. Collet, R. Storey, 2022, Thrombosis and Haemostasis.

Clinical Outcomes According to ECG Presentations in Infarct-Related Cardiogenic Shock in the Culprit Lesion Only PCI vs Multivessel PCI in Cardiogenic Shock Trial

J. J. Piek, E. Vicaut, H. Thiele, 2022, Chest.

Long-term follow-up of patients with sirolimus-eluting stents for treatment of bare-metal in-stent restenosis.

G. Helft, G. Montalescot, J. Collet, 2010, International journal of cardiology.

[2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.]

P. Kolh, J. Zamorano, P. Jüni, 2018, Kardiologia polska.

Antithrombin treatment in patients with non-ST-elevation acute coronary syndromes undergoing percutaneous coronary intervention

G. Montalescot, J. Collet, R. Dumaine, 2007 .

Ventricular conduction defects after transcatheter aortic valve implantation: a single-institute analysis.

P. Leprince, P. Cluzel, J. Collet, 2015, Artificial organs.

Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokinetic-pharmacodynamic relationships in stable coronary artery disease patients

G. Montalescot, J. Hulot, J. Collet, 2015, European Journal of Clinical Pharmacology.

PON1 Q192R genetic variant and response to clopidogrel and prasugrel: pharmacokinetics, pharmacodynamics, and a meta-analysis of clinical outcomes

E. Antman, J. Mega, M. Price, 2015, Journal of Thrombosis and Thrombolysis.

Thienopyridine-Associated Drug-Drug Interactions: Pharmacologic Mechanisms and Clinical Relevance

G. Montalescot, J. Hulot, J. Collet, 2011, Current cardiology reports.

Genetic substudy of the PLATO trial

G. Montalescot, J. Hulot, J. Collet, 2011, The Lancet.

Oral Antiplatelet Therapy

G. Montalescot, J. Collet, J. Silvain, 2010 .

Review: Platelet Function Testing and Implications for Clinical Practice

G. Montalescot, J. Collet, 2009, Journal of cardiovascular pharmacology and therapeutics.

Stent thrombosis: who's guilty?

G. Montalescot, J. Hulot, J. Collet, 2009, European heart journal.

Prasugrel monitoring and bleeding in real world patients.

P. Morange, G. Montalescot, M. Kerneis, 2013, The American journal of cardiology.

Effect of clopidogrel discontinuation at 1 year after drug eluting stent placement on soluble CD40L, P-selectin and C-reactive protein levels: DECADES (Discontinuation Effect of Clopidogrel After Drug Eluting Stent): a multicenter, open-label study

P. Serruys, J. Wykrzykowska, N. Curzen, 2009, Journal of Thrombosis and Thrombolysis.

Blunting periprocedural myocardial necrosis: Rationale and design of the randomized ALPHEUS study.

E. Vicaut, G. Montalescot, J. Collet, 2020, American heart journal.

Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study).

M. Dalby, J. Dubois-Randé, G. Montalescot, 2003, The American journal of cardiology.

Antiplatelet therapy in patients with ST-elevation myocardial infarction undergoing myocardial revascularisation: beyond clopidogrel

J. Wouter Jukema, J. Collet, L. De Luca, 2012, Current medical research and opinion.

Identification of poor response to P2Y12 inhibitors in ACS patients with a new ELISA-based vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation assay

G. Montalescot, M. Kerneis, J. Collet, 2013, Thrombosis and Haemostasis.

Slow response to clopidogrel predicts low response.

G. Montalescot, J. Collet, J. Silvain, 2010, Journal of the American College of Cardiology.

Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events.

F. Van de Werf, J. López-Sendón, G. Montalescot, 2005, European heart journal.

Preoperative Risk Levels and Vascular Access in Transcatheter Aortic Valve Implantation—A Single‐Institute Analysis—

P. Leprince, P. Cluzel, J. Collet, 2017, Artificial organs.

Outcome after revascularisation of acute myocardial infarction with cardiogenic shock on extracorporeal life support.

P. Leprince, G. Montalescot, J. Hulot, 2018, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Medium-term survival after primary angioplasty for myocardial infarction complicated by cardiogenic shock after the age of 75 years.

G. Helft, G. Montalescot, J. Collet, 2008, Archives of cardiovascular diseases.

Antithrombotic Therapy After Transcatheter Aortic Valve Replacement

G. Dangas, R. Mehran, B. Claessen, 2019, Circulation. Cardiovascular interventions.

New insights for low dosing with the new P2Y12 inhibitors.

G. Montalescot, M. Kerneis, J. Collet, 2014, Circulation journal : official journal of the Japanese Circulation Society.

Packaging is important: accelerated thrombolysis with encapsulated plasminogen activators

J. Weisel, J. Collet, 2004, Journal of thrombosis and haemostasis : JTH.

Glycoprotein IIb/IIIa receptors and primary stenting in acute myocardial infarction

G. Montalescot, J. Collet, R. Choussat, 2001 .

Radial versus femoral artery access for percutaneous coronary artery intervention in patients with acute myocardial infarction and multivessel disease complicated by cardiogenic shock: Subanalysis from the CULPRIT-SHOCK trial.

H. Thiele, S. Windecker, J. Piek, 2020, American heart journal.

Investigator Versus Core Laboratory Evaluation of Coronary Flow and Related Mortality in the CULPRIT-SHOCK Trial.

E. Vicaut, H. Thiele, G. Montalescot, 2019, Circulation. Cardiovascular interventions.

Pharmacological approaches of fibrin gel architecture modulation and thrombus degradation: its implication in atherogenesis and thromboembolism disease.

J. Soria, C. Soria, J. Collet, 1994, Thrombosis research.

Fibrinogen, a vascular risk factor: a simple marker or a real cause of vascular lesion?

J. Soria, C. Soria, J. Collet, 1994, Thrombosis research.

Effect of prasugrel pre-treatment strategy in patients undergoing percutaneous coronary intervention for NSTEMI: the ACCOAST-PCI study.

E. Vicaut, D. Dudek, G. Montalescot, 2014, Journal of the American College of Cardiology.

La gestion de l'arrêt des antiagrégants plaquettaires : un véritable enjeu médical Strategies to stop antiagregant treatment: a true medical stake

J. Collet, 2006 .

Fetuin-A is an independent predictor of death after ST-elevation myocardial infarction.

G. Montalescot, J. Collet, P. Guéret, 2007, Clinical chemistry.

Impact of coronary artery disease in patients undergoing transcatheter aortic valve replacement: Insights from the FRANCE‐2 registry

P. Leprince, J. Fajadet, J. Collet, 2017, Clinical cardiology.

Platelet effect of prasugrel and ticagrelor in patients with ST-segment elevation myocardial infarction.

G. Montalescot, M. Kerneis, J. Collet, 2015, Archives of cardiovascular diseases.

2020 Update of the quality indicators for acute myocardial infarction: a position paper of the Association for Acute Cardiovascular Care: the study group for quality indicators from the ACVC and the NSTE-ACS guideline group.

H. Thiele, C. Vrints, H. Bueno, 2021, European heart journal. Acute cardiovascular care.

Long-Term Mortality and Early€Valve€Dysfunction According€to€Anticoagulation Use

E. Vicaut, P. Leprince, B. Iung, 2019 .

Architecture of Intracoronary Thrombi in ST-Elevation Acute Myocardial Infarction

J. Weisel, G. Montalescot, J. Collet, 2006 .

Biomarkers of Thrombosis in ST-Segment Elevation Myocardial Infarction: A Substudy of the ATOLL Trial Comparing Enoxaparin Versus Unfractionated Heparin

E. Vicaut, G. Montalescot, M. Kerneis, 2018, American Journal of Cardiovascular Drugs.

Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation and coexistent atrial fibrillation.

H. Thiele, J. Collet, 2020, European heart journal.

Incidence and consequence of major bleeding in primary percutaneous intervention for ST-elevation myocardial infarction in the era of radial access: an analysis of the international randomized Acute myocardial infarction Treated with primary angioplasty and intravenous enoxaparin Or unfractionated h

E. Vicaut, K. Huber, G. Montalescot, 2015, American heart journal.

Incidence, delays, and outcomes of STEMI during COVID‐19 outbreak: Analysis from the France PCI registry

P. Lesault, G. Montalescot, J. Collet, 2020, Journal of the American College of Emergency Physicians open.

Is Pretreatment With P2Y 12 Inhibitors in Non–ST-Segment–Elevation Acute Coronary Syndrome Clinically Justified? Pretreatment with P2Y 12 Inhibitors in Non–ST-Segment– Elevation Acute Coronary Syndrome: An Outdated and Harmful Strategy C ONTrOvErSIES IN C ArDIOvASCULAr M EDICINE

G. Montalescot, J. Collet, J. Silvain, 2014 .

2018 ESC/EACTS Guidelines on myocardial revascularization.

Volkmar Falk, Fernando Alfonso, Peter Jüni, 2018, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis

P. Kolh, P. Schauerte, G. Filippatos, 2014, BMJ : British Medical Journal.

Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention.

Marco Valgimigli, Gregg W Stone, Matthew J Price, 2019, JACC. Cardiovascular interventions.

[2018 ESC/EACTS Guidelines on myocardial revascularization].

Volkmar Falk, Fernando Alfonso, Josef Niebauer, 2018, Kardiologia polska.

P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction

G. Montalescot, A. V. Van't Hof, J. Collet, 2015, Thrombosis and Haemostasis.

Abstract 4021: Clopidogrel 150 Mg/day to Overcome Low Responsiveness in Patients Undergoing Elective Percutaneous Coronary Intervention. Results from the Vasp-02 Randomized Study

J. Collet, L. Jacquemin, J. Cazenave, 2008 .

Antiplatelet Therapy and Coronary Artery Bypass Graft Surgery

G. Montalescot, J. Hulot, J. Collet, 2022 .

Dusart syndrome: a new concept of the relationship between fibrin clot architecture and fibrin clot degradability: hypofibrinolysis related to an abnormal clot structure.

J. Soria, C. Soria, J. Collet, 1993, Blood.

High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2).

G. Montalescot, J. Hulot, J. Collet, 2011, JACC. Cardiovascular interventions.

Incidence of, risk factors for and impact of readmission for heart failure after successful transcatheter aortic valve implantation.

E. Vicaut, P. Leprince, G. Montalescot, 2019, Archives of cardiovascular diseases.

Feasibility of outpatient coronary angiography with "ad hoc" angioplasty.

M. Komajda, G. Helft, G. Montalescot, 2008, Archives of cardiovascular diseases.

Vascular Access Site for TAVR: Use the Approach You Master Best.

J. Collet, J. Mesnier, 2020, JACC. Cardiovascular interventions.

Single Versus Dual Antiplatelet Therapy Following TAVR: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

C. Indolfi, G. Montalescot, M. Kerneis, 2021, JACC. Cardiovascular interventions.

Thrombotic dysfibrinogenemia. Fibrinogen "Caracas V" relation between very tight fibrin network and defective clot degradability.

J. Soria, C. Soria, J. Collet, 2000, Thrombosis research.

2018 ESC/EACTS Guidelines on myocardial revascularization.

P. Seferovic, P. Jüni, V. Falk, 2019, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Bleeding complications in patients with coronary stents during non-cardiac surgery.

C. Samama, J. Collet, J. Bosson, 2014, Thrombosis research.

Great Debate: Triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting should be limited to 1 week.

Deepak L. Bhatt, G. Hindricks, R. de Caterina, 2022, European heart journal.

Increased Expression of u-PA and u-PAR on Monocytes by LDL and Lp(a) Lipoproteins – Consequences for Plasmin Generation and Monocyte Adhesion

J. Soria, C. Soria, J. Collet, 1999, Thrombosis and Haemostasis.

Any room left for new antiplatelet agents in acute coronary syndrome?

G. Montalescot, J. Collet, 2013, European heart journal.

Measuring and reversing the effect of non-vitamin K antagonist oral anticoagulants (NOACs).

G. Montalescot, M. Kerneis, J. Collet, 2015, Circulation journal : official journal of the Japanese Circulation Society.

COVID-19 et assistance circulatoire

J. Collet, C. Frère, G. Hékimian, 2020, Annales de Cardiologie et d'Angéiologie.

Reasons for the Failure of Platelet Function Testing to Adjust Antiplatelet Therapy: Pharmacodynamic Insights From the ARCTIC Study.

E. Vicaut, G. Montalescot, J. Collet, 2019, Circulation. Cardiovascular interventions.

Apixaban and Valve Thrombosis After Transcatheter Aortic Valve Replacement: The ATLANTIS-4D-CT Randomized Clinical Trial Substudy.

E. Vicaut, P. Leprince, F. Neumann, 2022, JACC. Cardiovascular interventions.

Would Anyone Dare Abandon Repositioning of Self-Expanding TAVR?

J. Collet, O. Barthelemy, 2020, JACC. Cardiovascular interventions.

Questions and answers on antithrombotic therapy and revascularization strategies in non-ST-elevation acute coronary syndrome (NSTE-ACS): a companion document of the 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.

H. Thiele, A. Kastrati, J. Mehilli, 2020, European heart journal.

Early survival after acute myocardial infarction with ST-segment elevation: What could be improved? Insights from France PCI French registry

P. Lesault, J. Collet, F. Beygui, 2022, Medicine.

Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart

J. Grapsa, J. Mehilli, E. Grove, 2021, European heart journal.

Corrigendum to '2017 ESC/EACTS Guidelines for the management of valvular heart disease' [Eur J Cardiothorac Surg 2017;52:616-664].

Jeroen J. Bax, G. Hindricks, O. Alfieri, 2017, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

The 'Ten Commandments' for the 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.

H. Thiele, J. Collet, 2020, European heart journal.

Major bleeding and the ADP-binding enzyme creatine kinase in non-ST-segment elevation acute coronary syndromes.

H. Thiele, J. Collet, 2020, European Heart Journal.

Prasugrel over ticagrelor in non-ST-elevation acute coronary syndromes: is it justified?

H. Thiele, J. Collet, 2020, European heart journal.

Lesson learnt from the new 2020 ESC guidelines on non-ST-segment elevation acute coronary syndrome: when clinical judgement precedes and overpasses weak recommendations. 2020 non-ST-segment elevation acute coronary syndrome guidelines on pre-treatment: primum non nocere!

H. Thiele, J. Collet, 2020, European heart journal.

Questions and answers on coronary revascularization: a companion document of the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.

C. Patrono, M. Valgimigli, J. Collet, 2016, European heart journal.

Contrast-induced nephropathy: the sin of primary percutaneous coronary intervention?

G. Montalescot, J. Collet, J. Silvain, 2014, European heart journal.

Antithrombotic therapy in TAVI patients: changing concepts.

M. Valgimigli, J. Collet, G. Gargiulo, 2015, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Effect of Pre-Hospital Ticagrelor During the First 24 h After Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction: The ATLANTIC-H²⁴ Analysis.

E. Vicaut, W. Cantor, B. Merkely, 2015, JACC. Cardiovascular interventions.

Images in cardiovascular medicine. Architecture of intracoronary thrombi in ST-elevation acute myocardial infarction: time makes the difference.

J. Weisel, G. Montalescot, J. Collet, 2006, Circulation.

Pretreatment in the Setting of Non-ST-Elevated Acute Coronary Syndrome-When It Is Time to Change.

J. Collet, M. Zeitouni, 2021, JAMA network open.

Acute Cardiovascular Care

J. Collet, L. Bolognese, 2017 .

TAVR Patients Requiring Anticoagulation: Direct Oral Anticoagulant or Vitamin K Antagonist?

B. Iung, L. Labrousse, G. Rioufol, 2021, JACC. Cardiovascular interventions.

The efficacy of early versus delayed P2Y12 inhibition in percutaneous coronary intervention for ST-elevation myocardial infarction: a systematic review and meta-analysis.

Deepak L. Bhatt, R. Harrington, G. Montalescot, 2018, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Evaluation of neutrophil gelatinase-associated lipocalin and cystatin C as biomarkers of acute kidney injury after ST-segment elevation myocardial infarction treated by percutaneous coronary intervention.

G. Montalescot, M. Kerneis, J. Collet, 2019, Archives of cardiovascular diseases.

Acute Multivessel Coronary Occlusion Revealing COVID-19 in a Young Adult

G. Montalescot, J. Collet, P. Guedeney, 2020, JACC: Case Reports.

2020 ESC Guidelines on Sports Cardiology and Exercise in Patients with Cardiovascular Disease.

H. Heidbuchel, D. Corrado, P. Thompson, 2021, Revista espanola de cardiologia.

Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study

G. Montalescot, J. Hulot, J. Collet, 2009, The Lancet.

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.

Deepak L. Bhatt, F. Rutten, B. Lewis, 2020, European heart journal.

Coronary artery disease and revascularization associated with immune checkpoint blocker myocarditis: Report from an international registry.

K. Stangl, Joshua Levenson, K. Aonuma, 2022, European journal of cancer.

2018 ESC Guidelines for the diagnosis and management of syncope

Christophe Leclercq, Raffaello Furlan, Rose Anne Kenny, 2018, European heart journal.

Bedside monitoring of antiplatelet therapy for coronary stenting.

E. Vicaut, G. Montalescot, J. Collet, 2013, The New England journal of medicine.

Thrombosis after implantation of drug-eluting stents.

G. Montalescot, J. Collet, P. Albaladéjo, 2006, JAMA.

Does severe renal insufficiency increase the risk of bleeding after administration of low-molecular-weight heparin?

G. Montalescot, J. Collet, 2006, Nature Clinical Practice Nephrology.

Mechanisms and Definitions of Periprocedural Myocardial Infarction in the Era of Modern Revascularization

J. Collet, P. Guedeney, J. Silvain, 2022, Reviews in Cardiovascular Medicine.

Structural Studies of Fibrinolysis by Electron and Light Microscopy

C. Francis, J. Weisel, J. Collet, 1999, Thrombosis and Haemostasis.

Prevalence of factor V Leiden and prothrombin G20210A mutation in a large French population selected for nonthrombotic history: geographical and age distribution

L. Tiret, J. Collet, R. Guéguen, 2009, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[Reducing the risk of vascular complications during percutaneous aortic valve replacement].

P. Guyon, J. Collet, E. Teiger, 2012, Annales de cardiologie et d'angeiologie.

Cusp-Overlapping Projections in TAVR

J. Collet, O. Barthelemy, Redheuil, 2022, JACC: Cardiovascular Interventions.

Clonal Hematopoiesis in Cardiogenic Shock: Beyond Conventional Prognostication?

J. Hulot, J. Collet, Ghilas Rahoual, 2022, Journal of the American College of Cardiology.

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

B. Lewis, K. Khunti, G. Filippatos, 2020 .

Supraventricular Arrhythmia Following Patent Foramen Ovale Percutaneous Closure.

S. Crozier, G. Montalescot, J. Collet, 2022, JACC. Cardiovascular interventions.

Platelet function test-guided strategy: lost in translation?

G. Montalescot, J. Collet, J. Silvain, 2015, Circulation. Cardiovascular interventions.

Influence of &ggr;′ Fibrinogen Splice Variant on Fibrin Physical Properties and Fibrinolysis Rate

J. Weisel, G. Montalescot, J. Collet, 2004, Arteriosclerosis, thrombosis, and vascular biology.

Questions and answers on diagnosis and risk assessment: a companion document of the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation†.

C. Patrono, M. Valgimigli, J. Collet, 2020, European heart journal.

The alphaC domains of fibrinogen affect the structure of the fibrin clot, its physical properties, and its susceptibility to fibrinolysis.

J. Weisel, S. Lord, G. Montalescot, 2005, Blood.

P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention

Deepak L. Bhatt, Sunil V. Rao, P. Serruys, 2022, Nature Reviews Cardiology.

Long-Term Prognosis Value of Paravalvular Leak and Patient–Prosthesis Mismatch following Transcatheter Aortic Valve Implantation: Insight from the France-TAVI Registry

N. Jaussaud, B. Iung, J. Collet, 2022, Journal of clinical medicine.

Prevention and treatment of premature ischaemic heart disease with European Society of Cardiology Guidelines

G. Montalescot, M. Kerneis, J. Collet, 2022, Heart.

Ultrasound-based teaching of cardiac anatomy and physiology to undergraduate medical students.

J. Collet, A. Cohen, R. Isnard, 2013, Archives of cardiovascular diseases.

Questions and answers on antithrombotic therapy: a companion document of the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation†.

J. Zamorano, H. Baumgartner, C. Patrono, 2016, European heart journal.

Questions and answers on workup diagnosis and risk stratification: a companion document of the 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

F. Rutten, H. Thiele, A. Kastrati, 2020, European heart journal.

Heparin pretreatment in STEMI: is earlier always better?

J. Collet, M. Zeitouni, 2022, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokinetic-pharmacodynamic relationships in stable coronary artery disease patients

G. Montalescot, J. Hulot, J. Collet, 2015, European Journal of Clinical Pharmacology.

Enoxaparin anticoagulation monitoring in the catheterization laboratory using a new bedside test.

G. Montalescot, D. Costagliola, J. Collet, 2010, Journal of the American College of Cardiology.

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.

Deepak L. Bhatt, F. Rutten, B. Lewis, 2021, Revista espanola de cardiologia.

2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-segment Elevation.

Jeroen J. Bax, J. Mehilli, S. Windecker, 2015, Revista espanola de cardiologia.

Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis

G. Lip, E. Grove, Á. Lanas, 2016, European heart journal.

Can we override clopidogrel resistance?

G. Montalescot, J. Hulot, J. Collet, 2009, Circulation.

Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk” (Atherosclerosis (2019) 290 (140–205), (S0021915019314595), (10.1016/j.atherosclerosis.2019.08.014))

G. Hindricks, B. Lewis, M. Sabatine, 2019 .

On- Versus Off-Hours Presentation and Mortality of ST-Segment Elevation Myocardial Infarction Patients Treated With Primary Percutaneous Coronary Intervention.

G. Helft, G. Montalescot, M. Kerneis, 2019, JACC. Cardiovascular interventions.

Acute myocardial infarction after oral tranexamic acid treatment initiation.

G. Montalescot, J. Collet, D. Thomas, 2002, International Journal of Cardiology.

2017 EACTS Guidelines on perioperative medication in adult cardiac surgery.

J. Dunning, U. Landmesser, J. Collet, 2018, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

Editor's Choice - 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS).

Jeroen J. Bax, P. Kolh, I. Simpson, 2018, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

Genetics of the Response to Antithrombotic Drugs and the Need for Monitoring

G. Montalescot, J. Hulot, J. Collet, 2012 .

2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-segment Elevation.

Baris Gencer, Marco Valgimigli, Marco Roffi, 2015, Revista espanola de cardiologia.

2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.

G. Hindricks, B. Lewis, M. Sabatine, 2019, Atherosclerosis.

Intracardiac cement embolism during percutaneous vertebroplasty: incidence, risk factors and clinical management

J. Chiras, J. Collet, J. Spano, 2018, European Radiology.

ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2—care pathways, treatment, and follow-up

G. Hindricks, D. Andreini, T. Potpara, 2021, Cardiovascular research.

ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2—care pathways, treatment, and follow-up

G. Hindricks, D. Andreini, T. Potpara, 2021, European heart journal.

Dual antiplatelet therapy: optimal timing, management, and duration.

G. Montalescot, M. Kerneis, J. Collet, 2015, European heart journal. Cardiovascular pharmacotherapy.

Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.

Deepak L. Bhatt, M. Price, R. Becker, 2010, Journal of the American College of Cardiology.

Dynamic Changes of Fibrin Architecture during Fibrin Formation and Intrinsic Fibrinolysis of Fibrin-rich Clots*

J. Weisel, G. Montalescot, J. Collet, 2003, Journal of Biological Chemistry.

Disaggregation of In Vitro Preformed Platelet-Rich Clots by Abciximab Increases Fibrin Exposure and Promotes Fibrinolysis

J. Soria, C. Soria, G. Montalescot, 2001, Arteriosclerosis, thrombosis, and vascular biology.

2019 ESC/EAS Guidelines for management of dyslipidaemia: strengths and limitations.

G. Montalescot, M. Kerneis, J. Collet, 2020, European heart journal. Cardiovascular pharmacotherapy.

Impact of renal failure on all-cause mortality and other outcomes in patients treated by percutaneous coronary intervention.

G. Helft, G. Montalescot, M. Kerneis, 2015, Archives of cardiovascular diseases.

2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS).

V. Aboyans, L. Mazzolai, C. Vlachopoulos, 2018, Revista espanola de cardiologia.

Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases , in collaboration with the European Society for Vascular Surgery ( ESVS ) – Web Addenda

V. Aboyans, L. Mazzolai, C. Vlachopoulos, 2017 .

Imidazole propionate is increased in diabetes and associated with dietary patterns and altered microbial ecology

Luis Pedro Coelho, P. Bork, F. Bäckhed, 2020, Nature Communications.

European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1—epidemiology, pathophysiology, and diagnosis

G. Hindricks, D. Andreini, T. Potpara, 2021, European heart journal.

Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis.

C. Patrono, C. Baigent, A. Siegbahn, 2017, Journal of the American College of Cardiology.

Updates and current recommendations for the management of patients with non-ST-elevation acute coronary syndromes: what it means for clinical practice.

G. Montalescot, J. Collet, J. Silvain, 2015, The American journal of cardiology.

The (cid:1) C domains of ﬁbrinogen affect the structure of the ﬁbrin clot, its physical properties, and its susceptibility to ﬁbrinolysis

J. Weisel, S. Lord, G. Montalescot, 2005 .

Abnormal Fibrin Clot Architecture in Nephrotic Patients Is Related to Hypofibrinolysis: Influence of Plasma Biochemical Modifications

J. Soria, C. Soria, J. Collet, 1999, Thrombosis and Haemostasis.

High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study.

G. Montalescot, J. Hulot, M. Kerneis, 2012, European heart journal.

Epidemiology of atrial fibrillation in France: extrapolation of international epidemiological data to France and analysis of French hospitalization data.

J. Le Heuzey, O. Hanon, J. Blacher, 2011, Archives of cardiovascular diseases.

Exome sequencing of extreme clopidogrel response phenotypes identifies B4GALT2 as a determinant of on‐treatment platelet reactivity

U. Baber, J. Hulot, J. Collet, 2016, Clinical pharmacology and therapeutics.

Statin therapy is associated with lower prevalence of gut microbiota dysbiosis

Luis Pedro Coelho, P. Bork, V. Tremaroli, 2020, Nature.

Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis.

John Camm, Paulus Kirchhof, Gregory Y H Lip, 2011, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1—epidemiology, pathophysiology, and diagnosis

G. Hindricks, D. Andreini, T. Potpara, 2021, Cardiovascular research.

Myocardial infarction after endomyocardial biopsy in a heart transplant patient.

G. Montalescot, J. Collet, G. Drobinski, 2002, Journal of interventional cardiology.

Oral anticoagulants in coronary heart disease (Section IV) Position paper of the ESC Working Group on Thrombosis – Task Force on Anticoagulants in Heart Disease

G. Lip, C. Baigent, A. Siegbahn, 2016, Thrombosis and Haemostasis.

Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis.

E. Grove, C. Patrono, C. Baigent, 2018, European heart journal.

Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis.

G. Lip, R. de Caterina, E. Hylek, 2015, European heart journal.

2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease.

G. T. Gunnarsson, H. Heidbuchel, B. Lewis, 2020, European heart journal.

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.

P. Kolh, J. Zamorano, G. Levine, 2018, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

A prescription support-tool for chronic management of oral antithrombotic combinations in adults based on a systematic review of international guidelines

F. Tubach, J. Collet, R. Bun, 2019, PloS one.

2014 ESC/EACTS guidelines on myocardial revascularization.

P. Kolh, P. Schauerte, G. Filippatos, 2015, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[2014 ESC/EACTS Guidelines on myocardial revascularization].

P. Kolh, P. Schauerte, G. Filippatos, 2014, Kardiologia polska.

[Expert consensus of the French society of geriatrics and gerontology and the French society of cardiology on the management of atrial fibrillation in elderly people].

J. Le Heuzey, L. Fauchier, C. Leclercq, 2013, Geriatrie et psychologie neuropsychiatrie du vieillissement.

Expert consensus of the French Society of Geriatrics and Gerontology and the French Society of Cardiology on the management of atrial fibrillation in elderly people.

J. Le Heuzey, L. Fauchier, C. Leclercq, 2013, Archives of cardiovascular diseases.

Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis.

S. Scott, G. Montalescot, J. Hulot, 2011, JAMA.

Antiplatelet therapy after percutaneous coronary intervention.

A. Kastrati, J. Collet, D. Angiolillo, 2022, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

OP-EHEA210395_online 4013..4028

B. Lewis, V. Aboyans, L. Mazzolai, 2021 .

Guía ESC 2019 sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes (EASD)

B. Lewis, K. Khunti, G. Filippatos, 2020, Revista Española de Cardiología.

Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention

Deepak L. Bhatt, P. Serruys, G. Dangas, 2018, Nature Reviews Cardiology.

Early mineralocorticoid receptor blockade in primary percutaneous coronary intervention for ST-elevation myocardial infarction is associated with a reduction of life-threatening ventricular arrhythmia.

G. Montalescot, J. Collet, J. Silvain, 2013, International journal of cardiology.

CPAP for acute cardiogenic pulmonary oedema from out-of-hospital to cardiac intensive care unit: a randomised multicentre study

E. Vicaut, G. Montalescot, J. Collet, 2011, Intensive Care Medicine.

Optimizing long-term dual aspirin/clopidogrel therapy in acute coronary syndromes: when does the risk outweigh the benefit?

G. Montalescot, J. Collet, 2009, International journal of cardiology.

A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial.

G. Montalescot, P. Steg, J. Collet, 2006, Journal of the American College of Cardiology.

Antiplatelet agents for the treatment and prevention of atherothrombosis.

R. de Caterina, F. Van de Werf, F. Neumann, 2011, European heart journal.

Elderly Patients with ST-Segment Elevation Myocardial Infarction: A Patient-Centered Approach

G. Montalescot, M. Kerneis, J. Collet, 2019, Drugs & Aging.

Impact of red blood cell transfusion on platelet activation and aggregation in healthy volunteers: results of the TRANSFUSION study.

G. Montalescot, J. Collet, D. Brieger, 2010, European heart journal.

Fibrinogen Dusart: electron microscopy of molecules, fibers and clots, and viscoelastic properties of clots.

J. Soria, C. Soria, J. Weisel, 1996, Biophysical journal.

Contrast-induced acute kidney injury and mortality in ST elevation myocardial infarction treated with primary percutaneous coronary intervention

G. Helft, G. Montalescot, M. Kerneis, 2017, Heart.

Case-based implementation of the 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease.

M. Valgimigli, J. Collet, M. Roffi, 2018, European heart journal.

Expert position paper on the management of antiplatelet therapy in patients undergoing coronary artery bypass graft surgery

V. Falk, K. Huber, A. Leite-Moreira, 2014, European heart journal.

Composition of coronary thrombus in acute myocardial infarction.

J. Weisel, G. Montalescot, J. Collet, 2011, Journal of the American College of Cardiology.

Impact of transfer time on mortality in acute coronary syndrome with ST-segment elevation treated by angioplasty.

G. Montalescot, J. Collet, J. Silvain, 2012, Archives of cardiovascular diseases.

Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis.

G. Montalescot, J. Hulot, J. Collet, 2010, Journal of the American College of Cardiology.

Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the CHARISMA trial.

Deepak L. Bhatt, S. Steinhubl, E. Topol, 2009, Archives of cardiovascular diseases.

Aldosterone, mortality, and acute ischaemic events in coronary artery disease patients outside the setting of acute myocardial infarction or heart failure.

F. Mouquet, J. Dallongeville, S. Susen, 2012, European heart journal.

Early Aldosterone Blockade in Acute Myocardial Infarction: The ALBATROSS Randomized Clinical Trial.

E. Vicaut, F. Zannad, G. Montalescot, 2016, Journal of the American College of Cardiology.

High Plasma Aldosterone Levels on Admission Are Associated With Death in Patients Presenting With Acute ST-Elevation Myocardial Infarction

G. Montalescot, J. Collet, F. Beygui, 2006, Circulation.

Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis

P. Kolh, P. Schauerte, V. Falk, 2014, BMJ : British Medical Journal.

Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology.

D. Atar, R. de Caterina, K. Huber, 2011, European heart journal.

Trans-radial approach for catheterisation in non-ST segment elevation acute coronary syndrome: an analysis of major bleeding complications in the ABOARD Study

E. Vicaut, G. Montalescot, J. Collet, 2011, Heart.

Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes.

B. Asselain, K. Fox, G. Montalescot, 2005, Journal of the American College of Cardiology.

TransRadial Education and Therapeutics (TREAT): shifting the balance of safety and efficacy of antithrombotic agents in percutaneous coronary intervention: a report from the Cardiac Safety Research Consortium.

K. Anstrom, L. Newby, A. Jacobs, 2013, American heart journal.

Association of Serum Cholesterol Efflux Capacity With Mortality in Patients With ST-Segment Elevation Myocardial Infarction.

G. Montalescot, M. Kerneis, J. Collet, 2018, Journal of the American College of Cardiology.

Bleeding in the Elderly: Risk Factors and Impact on Clinical Outcomes After an Acute Coronary Syndrome, a Sub-study of the Randomized ANTARCTIC Trial

E. Vicaut, G. Montalescot, M. Kerneis, 2021, American Journal of Cardiovascular Drugs.

Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial

E. Vicaut, X. Combes, K. Huber, 2011, The Lancet.

Delphi-Consensus Weights for Ischemic and Bleeding Events to Be Included in a Composite Outcome for RCTs in Thrombosis Prevention

F. Tubach, P. Ravaud, C. Samama, 2011, PloS one.

Platelet P2Y12 Inhibitor Monotherapy after Percutaneous Coronary Intervention: An Emerging Option for Antiplatelet Therapy De-escalation

K. Huber, J. Collet, F. Verheugt, 2022, Thrombosis and Haemostasis.

Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention.

G. Biondi-Zoccai, M. Valgimigli, G. Trevi, 2007, The American journal of cardiology.

Usefulness of biomarker strategy to improve GRACE score's prediction performance in patients with non-ST-segment elevation acute coronary syndrome and low event rates.

Deepak L. Bhatt, E. Vicaut, H. Drexler, 2010, The American journal of cardiology.

[Fibrinogen, a vascular risk factor].

J. Soria, C. Soria, J. Collet, 1993, Bulletin de l'Academie nationale de medecine.

Thrombose de stents actifs à la rapamycine.

J. Collet, G. Drobinski, M. Fléron, 2004 .

Impact of non-steroidal anti-inflammatory drugs (NSAIDs) on cardiovascular outcomes in patients with stable atherothrombosis or multiple risk factors.

Deepak L. Bhatt, G. Montalescot, J. Collet, 2013, International journal of cardiology.

Short-term effects of the smoke-free legislation on haemostasis and systemic inflammation due to second hand smoke exposure

J. Ruidavets, A. Bura, G. Montalescot, 2011, Thrombosis and Haemostasis.

The P2Y12 receptor as a target of antithrombotic drugs

G. Montalescot, J. Collet, S. O’Connor, 2011, Purinergic Signalling.

Determinants of clinical presentation on outcomes in older patients with myocardial infarction

J. Golmard, J. Collet, A. Cohen, 2018, Geriatrics & gerontology international.

Cardiovascular Disease in the Elderly: Proceedings of the European Society of Cardiology-Cardiovascular Round Table.

S. Hohnloser, C. Leclercq, J. Collet, 2022, European journal of preventive cardiology.

Registry on acute cardiovascular events during endurance running races: the prospective RACE Paris registry.

J. Collet, B. Livarek, E. Teiger, 2016, European heart journal.

One-year clinical outcomes in patients with chronic renal failure treated by percutaneous coronary intervention with drug-eluting stent.

G. Helft, G. Montalescot, J. Collet, 2011, Archives of cardiovascular diseases.

Clinical Outcome of First‐ vs Second‐Generation DES According to DAPT Duration: Results of ARCTIC‐Generation

E. Vicaut, E. Belle, G. Montalescot, 2016, Clinical cardiology.

Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial

E. Vicaut, E. Belle, G. Montalescot, 2014, The Lancet.

Copeptin as a prognostic biomarker in acute myocardial infarction.

G. Montalescot, M. Kerneis, J. Collet, 2019, International journal of cardiology.

Inappropriate Use of Oral Antithrombotic Combinations in an Outpatient Setting and Associated Risks: A French Nationwide Cohort Study

F. Tubach, J. Collet, L. Zerah, 2021, Journal of clinical medicine.

Is the duration of dual antiplatelet therapy (DAPT) excessive in post-angioplasty in chronic coronary syndrome? Data from the France-PCI registry (2014–2019)

J. Collet, G. Rangé, G. Cayla, 2023, Frontiers in Cardiovascular Medicine.

The new European Society of Cardiology/European Association for Cardio-Thoracic Surgery recommendations for transcatheter aortic valve intervention are too restrictive.

H. Thiele, J. Collet, R. Mehran, 2022, European heart journal.

Timing of Invasive Coronary Angiography in NSTEMI.

S. Bangalore, J. Collet, 2023, JACC. Cardiovascular interventions.

Prevalence and clinical impact of Upper Gastrointestinal Symptoms in subjects treated with low dose aspirin: the UGLA survey.

G. Montalescot, J. Collet, F. Woimant, 2012, International Journal of Cardiology.

Background—Individualizing antiplatelet therapy after platelet function testing did not improve outcome after coronary stenting in the Assessment by a Double Randomization of a Conventional Antiplatelet Strategy Versus a Monitoring- Guided Strategy for Drug-Eluting Stent Implantation and of Treatmen

E. Vicaut, E. Belle, G. Montalescot, 2014 .

Pharmacogenetics of clopidogrel.

G. Montalescot, J. Hulot, J. Collet, 2012, Current pharmaceutical design.

Dose Effect of Clopidogrel Reloading in Patients Already on 75-mg Maintenance Dose: The Reload With Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term With Dual Antiplatelet Therapy (RELOAD) Study

G. Montalescot, J. Collet, J. Silvain, 2008, Circulation.

Optimal long-term antithrombotic treatment of patients with stable coronary artery disease and atrial fibrillation: OLTAT registry

G. Helft, J. Collet, Q. Fischer, 2017 .

Long-Term Mortality and Early Valve Dysfunction According to Anticoagulation Use: The FRANCE TAVI Registry.

E. Vicaut, P. Leprince, B. Iung, 2019, Journal of the American College of Cardiology.

Platelet function monitoring in elderly patients on prasugrel after stenting for an acute coronary syndrome: design of the randomized antarctic study.

E. Vicaut, G. Montalescot, J. Collet, 2014, American heart journal.

Coronary Angiographic Features and Major Adverse Cardiac or Cerebrovascular Events in People Living With Human Immunodeficiency Virus Presenting With Acute Coronary Syndrome.

D. Costagliola, P. Steg, J. Collet, 2022, Circulation. Cardiovascular interventions.

Platelet function testing to adjust antiplatelet therapy for elective coronary stenting: a landmark analysis of the ARCTIC trial

Eric Vicaut, E. Vicaut, E. Belle, 2013 .

Interleukin-1Beta and Risk of Premature Death in Patients with Myocardial Infarction.

E. Vicaut, G. Montalescot, M. Kerneis, 2020, Journal of the American College of Cardiology.

G. Helft, G. Montalescot, M. Kerneis, 2015, Archives of cardiovascular diseases.

Balloon-Expandable Versus Self-Expanding Transcatheter Aortic Valve Replacement

P. Leprince, B. Iung, G. Rioufol, 2019, Circulation.

Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy.

G. Lip, D. Atar, J. Morais, 2013, European heart journal.

Anaemia to predict outcome in patients with acute coronary syndromes.

G. Montalescot, J. Collet, N. Bouabdallaoui, 2013, Archives of cardiovascular diseases.

Statin therapy is associated with lower prevalence of gut microbiota dysbiosis

Luis Pedro Coelho, P. Bork, V. Tremaroli, 2020, Nature.

Special article 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.

P. Kolh, J. Zamorano, A. Kastrati, 2018, Revista Española de Cardiología.

Pharmacological remodeling of the thrombus architecture.

J. Soria, C. Soria, G. Montalescot, 1999, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Genetic and platelet function testing of antiplatelet therapy for percutaneous coronary intervention: the ARCTIC-GENE study

E. Vicaut, E. Belle, G. Montalescot, 2015, European Journal of Clinical Pharmacology.

Open issues in transcatheter aortic valve implantation. Part 1: patient selection and treatment strategy for transcatheter aortic valve implantation.

Raimund Erbel, Helmut Baumgartner, Philippe Pibarot, 2014, European heart journal.

Defining Strategies of Modulation of Antiplatelet Therapy in Patients With Coronary Artery Disease: A Consensus Document from the Academic Research Consortium

Deepak L. Bhatt, P. Serruys, M. Krucoff, 2023, Circulation.

Impact of coronary artery disease in patients undergoing transcatheter aortic valve replacement: Insights from the FRANCE-2 registry

P. Leprince, J. Collet, M. Gilard, 2018 .

Author Correction: Imidazole propionate is increased in diabetes and associated with dietary patterns and altered microbial ecology

Luis Pedro Coelho, P. Bork, F. Bäckhed, 2020, Nature Communications.

Erratum to "2019 ESC/EAS guidelines for the management of dyslipidemias: Lipid modification to reduce cardiovascular risk" [Atherosclerosis 290 (2019) 140-205].

G. Hindricks, B. Lewis, M. Sabatine, 2019, Atherosclerosis.

G. Helft, G. Montalescot, M. Kerneis, 2015 .

European practice patterns for antiplatelet management in NSTE-ACS patients: Results from the REal-world ADoption survey focus on acute antiPlatelet treatment (READAPT) survey.

C. Gale, G. Musumeci, J. Collet, 2023, International journal of cardiology.

Cardiovascular Risk in Clopidogrel-Treated Patients According to Cytochrome P 450 2 C 19 * 2 Loss-of-Function Allele or Proton Pump Inhibitor Coadministration

G. Montalescot, J. Hulot, J. Collet, 2022 .

Long-term outcome after bare-metal or drug-eluting stenting for allograft coronary artery disease.

A. Pavie, P. Leprince, M. Komajda, 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Intravenous Enoxaparin Versus Unfractionated Heparin in Elderly Patients Undergoing Primary Percutaneous Coronary Intervention

E. Vicaut, K. Huber, G. Montalescot, 2017, Angiology.

Acute, periprocedural and longterm antithrombotic therapy in older adults.

C. Patrono, B. Gigante, J. Morais, 2022, European heart journal.

2021 ESC/EACTS Guidelines for the management of valvular heart disease.

B. Prendergast, N. Freemantle, M. Jahangiri, 2021, European heart journal.

The Triple Challenge of Triple Therapy.

G. Montalescot, J. Collet, P. Guedeney, 2016, JACC. Cardiovascular interventions.

Impaired ristocetin–induced Platelet Aggregation in Whole Blood Assessed with a Multiplate© Analyser Suggests a New Mechanism of Antiplatelet Effect of Aspirin and Clopidogrel,

G. Montalescot, A. Baranger, J. Collet, 2011 .

Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study

G. Montalescot, J. Hulot, M. Kerneis, 2014, European Journal of Clinical Pharmacology.

Impact of a Prescription Support Tool to Improve Adherence to the Guidelines for the Prescription of Oral Antithrombotics: The Combi-AT Randomized Controlled Trial Using Clinical Vignettes

F. Tubach, J. Collet, M. Hauguel-Moreau, 2019, Journal of clinical medicine.

Life-threatening and major cardiac events during long-distance races: updates from the prospective RACE PARIS registry with a systematic review and meta-analysis.

G. Montalescot, J. Collet, P. Guedeney, 2020, European journal of preventive cardiology.

Corrigendum to "2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk" [Atherosclerosis 290 (2019) 140-205].

G. Hindricks, B. Lewis, M. Sabatine, 2019, Atherosclerosis.

Predictive factors of cardiac events after implantation of sirolimus-eluting stents for treatment of in-stent restenosis.

G. Montalescot, J. Collet, F. Beygui, 2006, International journal of cardiology.

βeta Blocker Interruption after Uncomplicated Myocardial Infarction: Rationale and Design of the randomized ABYSS trial.

E. Vicaut, G. Montalescot, J. Collet, 2023, American heart journal.

Bleeding complications in patients with coronary stents during non-cardiac surgery.

C. Samama, J. Collet, J. Bosson, 2014 .

Low molecular weight heparin after mechanical heart valve replacement.

P. Leprince, G. Montalescot, J. Collet, 2000, Circulation.

Jeroen J. Bax, J. Mehilli, S. Windecker, 2011, European heart journal.

[2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)].

J. Mehilli, S. Windecker, C. Patrono, 2016, Giornale italiano di cardiologia.

2023 ESC Guidelines for the management of acute coronary syndromes.

B. Lewis, S. Antoniou, L. Fauchier, 2023, European heart journal.

GRACE scores or high-sensitivity troponin for timing of coronary angiography in non-ST-elevation acute coronary syndromes.

Deepak L. Bhatt, C. Granger, S. Blankenberg, 2023, Clinical Research in Cardiology.

Determinants of invasive strategy in elderly patients with non-ST elevation myocardial infarction

J. Golmard, J. Collet, J. Boddaert, 2017, Journal of geriatric cardiology : JGC.

2021 ESC/EACTS Guidelines for the management of valvular heart disease.

B. Prendergast, N. Freemantle, M. Jahangiri, 2021, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

Platelet P2Y12 Inhibitor Monotherapy after Percutaneous Coronary Intervention: An Emerging Option for Antiplatelet Therapy De-escalation

K. Huber, J. Collet, F. Verheugt, 2022, Thrombosis and Haemostasis.

[2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation].

Jeroen J. Bax, J. Mehilli, S. Windecker, 2015, Kardiologia polska.

IMPACT OF MORPHINE ADMINISTRATION ON TICAGRELOR-INDUCED PLATELET INHIBITION IN ST-ELEVATION MYOCARDIAL INFARCTION PATIENTS TREATED BY PRIMARY PCI: RESULTS FROM THE PRIVATE-ATLANTIC STUDY

E. Vicaut, G. Montalescot, J. Collet, 2015 .

Percutaneous coronary intervention after fibrinolysis: a multiple meta-analyses approach according to the type of strategy.

G. Montalescot, J. Collet, M. Le May, 2006, Journal of the American College of Cardiology.

Subcutaneous enoxaparin with early invasive strategy in patients with acute coronary syndromes.

J. Golmard, G. Montalescot, J. Collet, 2004, American heart journal.

2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS).

V. Aboyans, L. Mazzolai, M. Czerny, 2018, Revista espanola de cardiologia.

[2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS)]

V. Aboyans, L. Mazzolai, C. Vlachopoulos, 2017, Kardiologia polska.

Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina.

E. Vicaut, G. Montalescot, J. Collet, 2000, Journal of the American College of Cardiology.

Management of antiplatelet therapy for non elective invasive procedures of bleeding complications: proposals from the French working group on perioperative haemostasis (GIHP), in collaboration with the French Society of Anaesthesia and Intensive Care Medicine (SFAR).

M. Mazighi, J. Collet, P. Fontana, 2019, Anaesthesia, critical care & pain medicine.

Ticagrelor to prevent restenosis: new drug for an old hypothesis?

G. Montalescot, J. Collet, G. Cayla, 2010, Arteriosclerosis, thrombosis, and vascular biology.

B. Lewis, J. Mehilli, S. Windecker, 2016 .

Interval From Initiation of Prasugrel to Coronary Angiography in Patients With Non – ST-Segment Elevation Myocardial Infarction

G. Montalescot, J. Collet, J. Tanguay, 2019 .

2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.

G. Hindricks, B. Lewis, M. Sabatine, 2019, Atherosclerosis.

[Coronary stents: 30 years of medical progress].

G. Montalescot, J. Collet, J. Silvain, 2014, Medecine sciences : M/S.

Aldosterone, mortality, and acute ischaemic events in coronary artery disease patients outside the setting of acute myocardial infarction or heart failure.

F. Mouquet, J. Dallongeville, S. Susen, 2012, European heart journal.

Safety and efficacy of IIb/IIIa inhibitors in combination with highly active oral antiplatelet regimens in acute coronary syndromes: A meta-analysis of pivotal trials

G. Montalescot, J. Collet, F. Beygui, 2017, Platelets.

Platelet function monitoring in elderly patients on prasugrel after stenting for an acute coronary syndrome: design of the randomized antarctic study.

E. Vicaut, G. Montalescot, J. Collet, 2014, American heart journal.

High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study.

G. Montalescot, J. Hulot, M. Kerneis, 2012, European heart journal.

New P2Y12 inhibitors versus clopidogrel in percutaneous coronary intervention: a meta-analysis.

G. Montalescot, J. Collet, D. Brieger, 2010, Journal of the American College of Cardiology.

Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI

E. Antman, J. Mega, B. Horne, 2017 .

Clinical outcomes according to ECG presentations in infarct-related cardiogenic shock in CULPRIT-SHOCK.

J. J. Piek, E. Vicaut, H. Thiele, 2020, Chest.

Regulation of fibrinogen biosynthesis by cytokines, consequences on the vascular risk.

J. Soria, C. Soria, J. Collet, 1996, Haemostasis.

Antiplatelet therapy and coronary artery bypass graft surgery a fallow land.

G. Montalescot, J. Hulot, J. Collet, 2010, Journal of the American College of Cardiology.

Heparin or enoxaparin anticoagulation for primary percutaneous coronary intervention

G. Montalescot, D. Costagliola, J. Collet, 2011, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis.

G. Montalescot, J. Hulot, J. Collet, 2010, Journal of the American College of Cardiology.

Endoscopy and antiplatelet agents. European Society of Gastrointestinal Endoscopy (ESGE) Guideline

C. Boustière, J. Collet, R. Laugier, 2011, Endoscopy.

P. Kolh, P. Schauerte, G. Filippatos, 2014, European heart journal.

Reply: Do not miss the elephant in the room: look at the red blood cells.

G. Montalescot, J. Collet, J. Silvain, 2014, Journal of the American College of Cardiology.

Anaemia to predict outcome in patients with acute coronary syndromes.

G. Montalescot, J. Collet, N. Bouabdallaoui, 2013, Archives of cardiovascular diseases.

[2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation].

Jeroen J. Bax, J. Mehilli, S. Windecker, 2015, Kardiologia polska.

Evaluation of a prescription support-tool for chronic management of oral antithrombotic combinations in adults using clinical vignettes: protocol of a randomised controlled trial